+DayWeekMonth−
Monday · Nov 9, 2026 · Health Digest · science

Boehringer's obesity drug survodutide did not raise heart risk in Phase 3 safety trial

The hazard ratio for the trial's main composite of heart-related events was 0.89, Boehringer and Fierce Biotech reported. Participants received weekly 3.6 mg or 6 mg doses or placebo for 72 weeks, and weight loss reached up to 13.7% at week 72, according to Boehringer and Fierce Biotech. The results were presented at the American Heart Association's Scientific Sessions and published in the Lancet, Boehringer said.

Discontinuation because of gastrointestinal side effects was 19.3% and 20.8% on the two doses, compared with 1.9% on placebo, Boehringer and Fierce Biotech reported. Boehringer said survodutide is not approved anywhere and that it is preparing regulatory submissions in obesity.

Why it matters: Boehringer and Fierce Biotech said it is the first global cardiovascular safety trial of a glucagon/GLP-1 dual agonist. Fierce Biotech said tolerability remains a question for the drug in a crowded weight-loss market.

References

  1. Boehringer Ingelheim's survodutide is the first glucagon/GLP-1 dual agonist to demonstrate a favorable cardiovascular safety profile in global Phase III SYNCHRONIZE-CVOT trial
    Boehringer Ingelheim · globenewswire.com · 2026-11-09
  2. AHA: Boehringer aims for 2027 survodutide submission after obesity drug passes cardio test
    Fierce Biotech · fiercebiotech.com · 2026-11-09
  3. Survodutide Meets CV Safety End Point in SYNCHRONIZE-CVOT
    AJMC · ajmc.com · 2026-11-09